<DOC>
	<DOCNO>NCT02193139</DOCNO>
	<brief_summary>This Phase 2 study design evaluate multiple dos anticholinergic-containing medication identify dose dos may effectively reduce axillary sweating hyperhidrotic subject . The anticholinergic agent study designate WL8713 .</brief_summary>
	<brief_title>Safety Efficacy Anticholinergic Agent Treatment Primary Axillary Hyperhidrosis</brief_title>
	<detailed_description />
	<mesh_term>Hyperhidrosis</mesh_term>
	<mesh_term>Cholinergic Antagonists</mesh_term>
	<criteria>Healthy volunteer primary axillary hyperhidrosis Poor quality life rating Hyperhidrosis Disease Severity Scale ( score 3 4 ) Has baseline gravimetric measurement spontaneous rest sweat production â‰¥100 mg/10 min room room temperature least one axilla Meets least two follow criterion ( selfreported ) : sweat bilateral symmetrical excessive sweating impairs daily activity subject experience least one sweat episode per week excessive sweating onset earlier age 25 year positive family history excessive sweating cessation sweat sleep</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>